- Genetic background, recent advances in molecular biology, and development of novel therapy in Alport syndrome
-
Nozu K, Takaoka Y, Kai H, Takasato M, Yabuuchi K, Yamamura T, Horinouchi T, Sakakibara N, Ninchoji T, Nagano C, Iijima K
- KMID: 2509802
- Kidney Res Clin Pract.
- 2020 Dec;39(4):402-413.
- doi: 10.23876/j.krcp.20.111
Alport syndrome (AS) is a progressive inherited kidney disease characterized by hearing loss and ocular abnormalities. There are three forms of AS depending on inheritance mode: X-linked Alport syndrome (XLAS), autosomal... -
- CITED
-
- Close
- SHARE
-
- Close
- A Call for a Rational Polypharmacy Policy: International Insights From Psychiatrists
-
Nakagami Y, Hayakawa K, Horinouchi T, Pereira-Sanchez V, Tan MP, Park SC, Park YC, Moon SW, Choi TY, Avasthi A, Grover S, Kallivayalil RA, Rai Y, Shalbafan M, Chongsuksiri P, Udomratn P, Kathriarachchi ST, Xiang YT, Sim K, Javed A, Chong MY, Tan CH, Lin SK, Inada T, Murai T, Kanba S, Sartorius N, Shinfuku N, Kato TA
- KMID: 2522486
- Psychiatry Investig.
- 2021 Nov;18(11):1058-1067.
- doi: 10.30773/pi.2021.0169
Objective Recently, rational polypharmacy approaches have been proposed, regardless of the lower risk and cost of monotherapy. Considering monotherapy as first-line treatment and polypharmacy as rational treatment, a balanced attitude... -
- CITED
-
- Close
- SHARE
-
- Close
